Home > About Kelly Chibale > Biosketch
About Kelly Chibale


Full Professor (ad hominem) at the University of Cape Town (2007). In 2008 awarded a Tier 1 South Africa Research Chair in Drug Discovery under the South Africa Research Chairs Initiative (SARChI) of the Department of Science and Technology (DST) and administered through the National Research Foundation (NRF). In 2009 became founding Director of the South African Medical Research Council (SAMRC) Drug Discovery and Development Research Unit at UCT. In the same year (2009) elected Fellow of UCT and the Royal Society of South Africa. In 2010 became the founding Director of the UCT Drug Discovery and Development Centre (H3D).  Elected a Fellow of the Royal Society of Chemistry (RSC), UK in 2014.  Awarded a 2-year Cheney Visiting Fellowship at the University of Leeds in the UK and the SAMRC Gold Medal for 2016.  Research has been in the field of anti-infective (malaria, tuberculosis, schistosomiasis) drug discovery and has been underpinned by (Hit to Lead and Lead Optimization) medicinal chemistry.  Drug discovery research has also extended to the structure-guided design and synthesis of domain-selective inhibitors of angiotensin converting enzyme for cardiovascular and fibrosis disease indications in collaboration with Prof Edward D. Sturrock (IDM).  Current funding sources include Technology Innovation Agency (TIA), SAMRC, Strategic Health Innovation Partnerships (SHIP) unit of the SAMRC, NRF, Medicines for Malaria Venture (MMV), Novartis Research Foundation, Merck, Celgene Global Health and the Bill and Melinda Gates Foundation (BMGF).